Intravenous immunoglobulin in neonatal group B streptococcal disease. Pharmacokinetic and safety studies in monkeys and humans.
Am J Med
; 76(3A): 117-23, 1984 Mar 30.
Article
en En
| MEDLINE
| ID: mdl-6424443
ABSTRACT
Numerous studies have suggested that opsonic antibody is important in neonatal immunity to group B streptococci. Immunoglobulin G is primarily transferred from the mother to the fetus across the placenta in the last few weeks of pregnancy. Premature babies may, therefore, not acquire sufficient opsonic antibody to protect them from infection with group B streptococci. Although maternal immunization may provide adequate maternal opsonic antibody, premature infants with antibody deficiency may remain susceptible to infection. Intravenous immunoglobulin administered to term pregnant rhesus monkeys did not provide reliable levels of serum opsonic activity to group B streptococci in their offspring. Pharmacokinetic and safety studies were also performed in human neonates. Significant elevations in group B streptococcal-specific IgG did occur in human neonates given 500 mg/kg intravenous immunoglobulin and the infusions appeared safe and well tolerated. The availability of intravenous immunoglobulin with functional activity against group B streptococci may provide a rapid and effective method of delivering opsonic antibody to neonates.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Infecciones Estreptocócicas
/
Inmunoglobulina G
/
Enfermedades del Recién Nacido
Tipo de estudio:
Etiology_studies
Límite:
Adult
/
Animals
/
Female
/
Humans
/
Newborn
/
Pregnancy
Idioma:
En
Revista:
Am J Med
Año:
1984
Tipo del documento:
Article